U.S. regulators cleared the first generic competitor to Mylan'sEpiPen, after a yearslong delay that many said contributed to the emergency allergy drug's rapid rise in price.
U.S. regulators cleared the first generic competitor to Mylan'sEpiPen, after a yearslong delay that many said contributed to the emergency allergy drug's rapid rise in price.